From September 25th to 28th, the 92nd Congress of the German Society for Neurology took place in Stuttgart. The congress covers the entire spectrum of scientific and clinical neurology, but of course MS – as
Continue reading
Tysabri® (active ingredient Natalizumab) is a highly effective medication, but it has the significant problem of PML risk – you have already read this statement here quite often. Despite this serious side effect, I advocate
Continue reading
As of this week, Ocrevus® (Ocrelizumab) is available for prescription and in pharmacies for the treatment of relapsing-remitting (RMS) and primary progressive Multiple Sclerosis (PPMS). Given the good clinical efficacy data and acceptable safety profile,
Continue reading
Things are happening. After many years of no real therapeutic options for chronic progressive Multiple Sclerosis and many therapy studies have been negative, two substances have now actually shown significant effects on disability progression in
Continue reading
The annual ECTRIMS (European Committee for Treatment and Research in Multiple Sclerosis) conference took place during the second week of October. Over 9,000 clinical and scientific MS experts from all regions of the world gathered
Continue reading
Unsere Website verwendet Cookies und sammelt dabei Informationen über Ihren Besuch, um unsere Website zu verbessern (durch Analyse), Ihnen Social Media-Inhalte und relevante Werbung anzuzeigen. Weitere Informationen finden Sie auf unserer Seite . Sie können zustimmen, indem Sie auf die Schaltfläche "Akzeptieren" klicken.
Cookie-Einstellungen
Unten können Sie auswählen, welche Art von Cookies Sie auf dieser Website zulassen. Klicken Sie auf die Schaltfläche "Cookie-Einstellungen speichern", um Ihre Auswahl zu übernehmen.
Dieser Inhalt ist gesperrt. Akzeptieren Sie Cookies in der Kategorie '%CC%', um diesen Inhalt anzuzeigen.
